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Abstract
Background: Subjective expectations regarding future health may influence patients’ judgement of current health
and treatment effects, as well as adherence to therapies in chronic diseases. We aimed to explore subjective
expectations on longevity and future health-related quality of life (HRQOL) of patients with age-related macular
degeneration (AMD) treated with antiVEGF injections and analyse the influencing factors.
Methods: Consecutive AMD patients in two ophthalmology centres were included. Demographics, clinical
characteristics and informal care utilisation were recorded. Current health was evaluated by the EQ-5D generic
health status questionnaire and time trade-off (TTO) methods. Happiness was measured on a visual analogue
scale (VAS). Subjective life-expectancy and expected EQ-5D status at ages 70, 80 and 90 were surveyed. T-test was
applied to compare subgroups and Pearson correlations were performed to analyse relationships between variables.
Results: One hundred twenty two patients were involved (females 62%) with a mean (SD) age of 75.2 (7.9) years and
disease duration of 2.9 (2.5) years. The majority were in AREDS-4 state, the better eye’s ETDRS was 64.7 (15.4). EQ-5D
and TTO revealed moderate deterioration of health (0.66 vs. 0.72, p = 0.131), happiness VAS was 6.3 (2.2). Correlation
between EQ-5D and ETDRS was moderate (R = 0.242, p < 0.05) and having both versus one eye in AREDS-4 resulted
lower TTO (0.68 vs. 0.83; p = 0.013). Subjective life-expectancy did not differ significantly from statistical life-expectancy
and had no significant impact on TTO. The self-estimated mean EQ-5D score was 0.60, 0.40 and 0.24 for ages 70, 80 and
90 which is lower than the population norm of age-groups 65–74, 75–84 and 85+ (0.77, 0.63 and 0.63, respectively). Age,
gender, current EQ-5D, need for informal care and happiness were deterministic factors of subjective health expectations.
Conclusion: AMD patients with antiVEGF treatment have comparable HRQOL as the age-matched general
public but expect a more severe deterioration of health with age. Older patients with worse HRQOL have worse
subjective expectations. Exploring patients’ health expectations provides an opportunity for ophthalmologists
to correct misperceptions and improve the quality of AMD care. Further studies should provide evidences on the
relationship between subjective expectations and actual health outcomes, and on its impact on patients’ AMD-specific
health behaviour.
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life-expectancy, Health expectations
* Correspondence: marta.pentek@uni-corvinus.hu
1Department of Health Economics, Corvinus University of Budapest, Fővám
tér 8, Budapest 1093, Hungary
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Péntek et al. BMC Geriatrics  (2017) 17:233 
DOI 10.1186/s12877-017-0619-9
Background
Age-related macular degeneration (AMD) is one of the
main causes of vision loss in adulthood in developed
countries [1]. People with AMD often develop other
health issues as well, patients often suffer from depres-
sion which has a negative impact on their health [2, 3].
Exudative form (also called wet AMD) resulted in irre-
versible severe visual impairment until the introduction
of the highly effective anti-vascular endothelial growth fac-
tor (antiVEGF) biological treatments. Patient-physician
collaboration holds promise for improving patient care
because antiVEGF therapy requires regular monitoring
and re-treatments might be necessary to preserve the
beneficial effects [4].
Patient-physician communication about the expected
benefits and risks of the antiVEGF therapy as well as to
get insight into patient’s preferences and views for their
future health is an integral part of the clinical practice
[5]. However, subjective expectations are rarely observed.
One way to overcome the problem is to elicit future
health beliefs of individuals, or so-called subjective
health expectations, directly from the patients by sur-
veys. All AMD patients live with some uncertainty about
the course of the disease, future health, including lon-
gevity, health related quality of life (HRQL) and happi-
ness [6]. Happiness is considered as a subjective
measure of the overall satisfaction of life, generally de-
fined as ‘the degree to which an individual judges the
overall quality of his life favourably’ and is frequently
designated as an important life goal [7–9].
Some patients anticipate a great discomfort related to
the antiVEGF treatment and experience the intravitreal
injections as stressful events, especially in the beginning
of the treatment [10, 11]. Comparing and valuing this
short term burden and expected long term health benefits
from the antiVEGF treatment might influence patients’
participation in AMD care and treatment adherence. Pre-
vious studies including the general population revealed
that individuals tend to overestimate their life-expectancy
and underestimate their health-related quality of life
(HRQOL) for future ages [12, 13]. Age and current health
state were found to be important explanatory factors for
subjective health expectations. Brouwer and van Exel
highlighted the importance of subjective health expecta-
tions studies given the influence inaccurate expectations
may have on actual health behaviour, treatment participa-
tion in health care and acceptance of lifestyle changes
[12]. Exploring patient’s subjective health expectations has
an increasing role in clinical decision-making, however no
study results available in AMD.
Subjective health expectations are important from the
health economics aspect as well. Highly effective but
costly biological therapies have increased interest in the
economic aspects of AMD treatments [4, 14–18]. To
conduct a proper economic analysis, data on the value
of different health states expressed in utility are required.
Utilities are used to calculate the quality-adjusted life
year (QALY) gains of different treatment strategies in
cost-effectiveness analyses. Health state utility values in
AMD were analysed in two recent systematic literature
reviews and the time trade-off (TTO) method was found
to be a suitable health state valuation technique in AMD
[19, 20]. The TTO consists of a hypothetical trade-off
in which subjects are asked to indicate the number of
life-years they would be willing to sacrify to avoid a
well-defined poorer health state [21–23]. Subjective ex-
pectations on longevity and future health may influence
TTO responses [24].
In this paper we present findings on subjective health
expectations of patients with AMD treated with antiVEGF
biologicals in Hungary. We assess patients’ HRQOL in-
cluding two health state utility measures, namely the EQ-
5D and TTO [25]. We analyse the correlations among
subjective health expectations, patients’ current visual
status and HRQOL, patients’ dependence on others and
patients’ happiness.
Methods
Study design and patients
We conducted a non-interventional, cross-sectional ques-
tionnaire survey in two university ophthalmology clinics
in Hungary, involving patients and their ophthalmologists.
Patients with diagnosis of wet AMD on at least one eye
confirmed by ophthalmologist, aged ≥ 18 years and who
were treated with or were eligible to begin biological intra-
vitreal treatment were invited to participate in the
study. Recruitment run between November of 2012 and
December of 2013 and patients who gave written in-
formed consent to participate in the study were con-
secutively enrolled. The study was performed in
accordance with the Declaration of Helsinki. Ethical ap-
proval was obtained from the national ethical committee
(ETT–TUKEB7946/2013/EKU).
Questionnaire survey
The questionnaire consisted of two main sections: the first
section was completed by the patients and the second was
filled by their ophthalmologists (Additional file 1). Patients
completed a set of questions in which socio-economic
data, health care utilisation, self-assessed disease activity
on Visual Function Index-14 (VF-14), health related
quality of life measured by EQ-5D questionnaire, and
utility of the current health status assessed by time-
trade-off (TTO) and happiness were surveyed. (See
next sections.)
AMD related clinical data (date of diagnosis, vision by
Early Treatment Diabetic Retinopathy Study - ETDSR,
Age-Related Eye Disease Study - AREDS state and
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therapies in the past 12 months, current treatment) and
comorbidities were provided by ophthalmologists [26, 27].
Self-completed questionnaire survey - the patients
Patients who had difficulties with reading due to visual
problems were helped by an interviewer who read the
questions and recorded answers. Demographics and em-
ployment status was surveyed, as well as the number of
AMD related hospitalizations in the previous 12 months
and informal care due to AMD was assessed for the past
month (the number of hours per week provided by
others to help the patient in his/her everyday activities).
A Hungarian translation of the Visual Function Index-
14 (VF-14) was used to assess disease-specific functional
status. The VF-14 ranges between 0 (not affected) to 100
(extremely affected), the higher scores correspond to a
higher impairment [28].
Current health related quality of life (HRQOL): EQ-5D,
time-trade-off (TTO) and happiness
We applied two methods to assess patients’ current
HRQOL, both provide utility values on the current
health state: EQ-5D and TTO.
The validated Hungarian version of the EQ-5D ques-
tionnaire was completed by the patients which comprises
a descriptive system (EQ-5D-3 L) and a Visual Analogue
Scale (EQ VAS, with endpoints labelled as ‘Worst imagin-
able health state’ and ‘Best imaginable health state’, range
0–100) [25]. The descriptive system distinguishes between
five health domains (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression), and three health
state levels for each health domain corresponding to no
problems, some problems, and severe problems. The pa-
tient was asked to indicate his/her current health state in
each of the five dimensions. A HRQOL utility score (the
EQ-5D score), as valued by the general public, was calcu-
lated from the patient reported health status on the de-
scriptive system. Due to lack of national dataset the UK
tariffs were applied for the calculation (range -0.594 – 1).
Time trade-off (TTO) is a broadly used method to meas-
ure health state utility directly among patients [29–31].
First, patients were asked to indicate the age they ex-
pected to reach. In the next question, they were asked to
estimate how many years they would sacrify of their
remaining lifetime in return for perfect vision. Utilities
were calculated by the following functions where U de-
notes utility, r is the self-estimated remaining lifespan
and x is sacrificed life-years:
U ¼ 1–x=r:
For instance, a respondent who traded 2 years of his
remaining lifespan of 10 years to live with perfect vision,
the utility would be U = 1–2/10 = 0.8.
Patients were asked to value their happiness as well,
i.e. how much happy they feel in general. A 0–10 visual
analogue scale (VAS) was used in which the two end-
points were defined as ‘very unhappy’ and ‘very happy’.
Subjective expectations for future HRQOL and longevity
Patients were asked to estimate their expected HRQOL at
older ages. To make the expectations comparable to
current HRQOL, statements of the EQ-5D descriptive sys-
tem were applied for the assessment (Additional file 1).
Patients had to imagine that they were at the age of 60,
70, 80 and 90 years, respectively, and indicate the level of
health deterioration they expected to have at these ages in
each domain of the EQ-5D. If patients responded to ques-
tions about future life years that they had already reached,
answers were excluded. This methodology was previously
used in the Netherlands and as well in Hungary in a large
expectation survey on the general population, and also in
recent Hungarian studies with rheumatoid arthritis and
psoriasis patients [12, 13, 32]. Subjective life-expectancy
was surveyed as detailed above at the TTO section.
Analysis of determinants of subjective health
expectations
Subgroups were developed by patients’ demographic and
clinical characteristics: visual status measures, AMD-
related hospitalisation in the past 12 months and informal
care use. Subgroups for ‘survivors’ vs. ‘non-survivors’ were
also established: subjective HRQOL expectations for ages
between 60 and 90 were analyzed for subgroups who be-
lieve to reach that age (so called ‘survivors’) and for those
who do not (‘non-survivors’). Previous studies revealed
that patients’ beliefs on longevity might influence consid-
erably their subjective HRQOL expectations for future
ages [12, 13, 32]. These subgroups were used to compare
subjective life-expectancy and future HRQOL expecta-
tions results.
Subjective expectations on longevity were compared to
the gender- and age-matched statistical life expectancy
in Hungary [33]. Determinants of over- and underesti-
mation were analyzed. Correlations between current vis-
ual status (ETDRS, VF-14) and HRQOL outcomes (EQ-
5D, TTO and happiness VAS) were analyzed, as well as
their relations with subjective expectations on longevity
and future HRQOL. Patients’ age was also considered in
this analysis.
Statistical analysis
Statistical analysis of the data was carried out using SPSS
Version 20.0 for Windows. Descriptive statistics were
performed, T-test was applied to compare subgroups
and Pearson correlations were performed to analyse rela-
tionships between variables. The level of significance
was set to 0.05.
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Results
Sample characteristics
Altogether 122 patients completed the questionnaire,
62% were female. Mean age of the patients was 75.2 (SD
7.9, range: 56–90) years and the disease duration was 2.9
(SD 2.5) years. Main characteristics and visual status of
the patients are presented in Table 1.
Twenty-six patients (21%) were admitted to hospital
due to AMD in the past 12 months. Altogether 35 pa-
tients (29%) required help from others for everyday ac-
tivities (informal care) due to AMD (Table 2).
Current HRQOL and its relations with visual status
The average utility score by the EQ-5D was higher than
with the TTO and the difference was 0.06 (p = 0.131).
Happiness, as measured on a 0–10 VAS, was mean 6.3
(SD 2.2) (Table 2) The only statistically significant differ-
ence identified on all current HRQOL outcomes was for
those who used home help in the last month.
The current EQ-5D score (mean 0.65, SD 0.34) was
not statistically different compared to the age-matched
general population’ values in Hungary (Fig. 1).
Correlations between EQ-5D score and visual acuity of
left and right eyes were not significant, however, signifi-
cant moderate correlation was found between visual
acuity of the better eye and EQ-5D score (Table 3). The
average EQ-5D score of patients with AREDS-4 in both
eyes was lower than with AREDS-4 only in one eye
(0.63 (SD 0.35) vs. 0.72 (SD 0.28)), the difference was
not significant (p = 0.17).
In contrast, direct utility scores measured by TTO did
not correlate with visual acuity of left, right or the better
eye (Table 3). However, significant differences were re-
vealed between subgroups of AREDS-4 in both eyes and
one eye (TTO: 0.68 vs. 0.84; p = 0.013). Patients who
have already had antiVEGF therapy expected signifi-
cantly better HRQOL for ages 80 and 90 compared to
those who were only eligible but not yet experienced
with this treatment. General happiness VAS did not cor-
relate with visual acuity and did not differ between
AREDS states either.
Subjective life expectancy and its determinants
Subjective expectations regarding remaining life years
were in line with patients’ gender- and age-matched
statistical life expectancy (10.4 and 10.2, p = 0.980).
Subgroup analysis by gender revealed that females
underestimated their life-expectancy by 0.8 years, while
males overestimated by 1.6 years (p = 0.051).
Age and self-reported general happiness showed sig-
nificant moderate positive correlation, while EQ-5D
score, EQ VAS, VF-14 and visual acuity showed no sta-
tistically significant correlation with subjective life-
expectancy. Neither the number of expected remaining
Table 1 Main characteristics of patients
Variables Mean (SD)/N (%)
Males 46 (38)
Age, year 75.2 (7.9)
Highest educational level (n = 121)
- Primary school 37 (31)
- Secondary school 53 (44)
- College (Bsc) 15 (12)
- University (Msc) 16 (13)
Lives in the same household (n = 121)
- Alone 43 (35)
- With others 78 (64)
Residence (n = 121)
- Capital (Budapest) 46 (38)
- County town 16 (13)
- Other town 39 (32)
- Village 20 (17)
Employment statusa (n = 122)
- Active, works in a payed job full time 2 (2)
- Active, works in a payed job part time 0 (0)
- Disability pensioner 2 (2)
- Retired 119 (98)
- Unemployed 0 (0)
Comorbidityb (n = 122)
- Parkinson disease 1 (1)
- Diabetes 21 (17)
- Hypertension 82 (67)
- Depression 12 (10)
Visual acuity (ETDRS 0–100)
- Left eye 49.8 (27.0)
- Right eye 42.6 (29.0)
better eye (greater ETDRS score) 64.7 (15.4)
AREDS categories, left eye
- AREDS 1 5 (4)
- AREDS 2 1 (1)
- AREDS 3 9 (8)
- AREDS 4 98 (87)
AREDS categories, right eye
- AREDS 1 8 (7)
- AREDS 2 2 (2)
- AREDS 3 2 (2)
- AREDS 4 104 (89)
Both eyes in AREDS 4 84 (69)
a1 retired patient was working
bpatients could have more than one comorbidities
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life years nor the accuracy of the life-expectancy estima-
tion correlated with TTO results (Table 3).
Age was in moderate positive correlation with the ac-
curacy of patients’ life expectancy estimation. Younger
patients were more likely to underestimate whilst older
ones to overestimate their life expectancy compared to
the average statistical gender- and age-matched life ex-
pectancy (R = 0.329, p < 0.001). Also self-reported hap-
piness was in positive association with the accuracy of
patients’ life expectancy estimation, happier patients
tend to overestimate their life expectancy (R = 0.221,
p = 0.022).
Subjective expectations for future HRQOL and its
determinants
The majority of patients were older than 60 years,
therefore HRQOL expectations related questions were
relevant where patients were under age 70 (27%), 80
(54%) and 90 (57%). Patients expected a severe de-
crease of their HRQOL with age, from an average
EQ-5D score of 0.60 at age 70 to 0.24 at age 90.
Similar tendency was observed in a survey among the
general population of age 55 and over, however, AMD
patients seem to have somewhat more optimistic be-
liefs [13] (Fig. 1).
Fig. 1 Comparison of subjective health-related quality of life (HRQOL) expectations in EQ-5D for older ages between AMD patients and the
general population. General population and AMD patients between the age of 55–64, 65–74, 75–84 and 85–94 represent the age of 60, 70, 80
and 90 respectively. Expectations for age 60 of AMD patients are not depicted here since only three patients were < 60 years and answering
expectation questions. Comparing future HRQOL expectations with actual health status of the age matched patients within the sample, actual
EQ-5D scores exceeded the expectations (age of 60: 0.59 vs. 0.56, P > 0.05; age of 70: 0.73 vs. 0.38, P < 0.01). Sources: [13, 35]
Table 3 Correlations between subjective health expectations, happiness and continuous variables
Variables EQ-5D
utility (0–1)
TTO utility
(0–1)
Happiness
(0–10)
Expected remaining
life years
Accuracy of life
expectancy estimation
Expected EQ-5D scores for
future ages
70y 80y 90y
Age −0.032 −0.114 −0.358 0.329 0.366 0.289 0.052
ETDRS score in better eye 0.241 0.147 0.065 0.119 0.029 0.035 0.044 0.025
ETDRS score in worse eye 0.088 0.016 −0.022 0.078 −0.073 −0.013 −0.053 −0.157
VF-14 (0–100) 0.373 0.180 0.099 0.085 −0.048 0.191 0.151 0.168
TTO utility (0–1) 0.157 – 0.286 0.072 0.078 0.359 0.078 0.217
Current EQ-5D index score – 0.157 0.146 0.112 0.098 0.642 0.357 0.451
Current EQ VAS (0–100) 0.387 0.144 0.212 0.182 0.162 0.432 0.323 0.266
Current general happiness
VAS (0–10)
0.146 0.286 – 0.298 0.221 0.114 0.267 0.532
Bold: Correlation is significant at the p < 0.05 level
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Among demographic variables, both age and gender
were in significant association with future HRQOL
expectations. Women expected for the future ages con-
siderably lower HRQOL than men (Table 2). Age was in
moderate positive correlations with future expectations,
as older patients expected better HRQOL (Table 3). In
other words, respondents with age closer to the ques-
tioned age expected better HRQOL.
Patients’ current HRQOL as measured by the EQ-5D
and assessment about their happiness (on a 0–100 mm
visual analogue scale) significantly correlated with future
expectations. Higher score on patient reported happiness
resulted in better self-estimated HRQOL for ages 80 and
90 years (Table 3). Results of linear regression analysis
confirmed these findings indicating that age, current
health status (EQ-5D and EQ VAS) and happiness VAS
were significant determinants of future subjective health
expectations (data will be sent on request).
Discussion
This study provides data on subjective health expecta-
tions for the future in an AMD patient population who
were eligible for or have experienced treatment with
antiVEGF therapy. This is the first research in the lit-
erature to assess subjective health expectations of
AMD patients and to explore the determinants. To
study the relations between current visual status
(AREDS, ETDRS), HRQOL and subjective expectations
for future health, the VF-14 and two health state utility
measures (the EQ-5D and the time trade-off ) were ap-
plied and some further potentially influencing factors
were also considered.
Our study showed that in this AMD population with
high rate (76%) of biological drug treatment, patients’
EQ-5D scores were similar to those of age matched
general population. This finding suggests that the
generic health state measure EQ-5D is not able to cap-
ture the negative impact of AMD. The slight correlation
between the EQ-5D score and visual acuity, and the
statistically not significant difference of EQ-5D scores
between AREDS states seem to strengthen this hypothe-
sis. In contrast, the direct health status utility measure-
ment, the TTO method, better distinguished between
patients with different AREDS state (Tables 2 and 3).
One possible reason of the different behaviour of the
two health state utility measures and of their weak cor-
relation is the difference in their anchor points, as EQ-
5D was anchored to perfect health and TTO utility was
anchored to perfect vision. Another disparity that might
count is that the EQ-5D score presents societal values of
health states whilst the TTO reflects patients’ evalua-
tions. Our findings are in line with and confirm the con-
clusions of previous systematic reviews on utility
measurement in wet AMD [19, 20]. Pearson et al. found
that the TTO measurement is a better indicator of the
impact of visual acuity on HRQOL than the EQ-5D.
However, our study highlighted a new aspect, namely
that both EQ-5D and TTO utilities were significantly
lower in AMD patients who received help from others
to perform everyday activities. Altogether 86% of pa-
tients using informal care had both eyes in AREDS-4,
while 36% of patients having both eyes in AREDS-4 re-
ceived informal care. EQ-5D utility difference was four
times higher between informal care utiliser and non-
utiliser subgroups than between AREDS subgroups (0.35
vs. 0.09). These data indicate that self-care ability was
the determinant influential factor.
AMD patients expected a worse HRQOL for older
ages than the general population in Hungary actually
has in the respective ages. (Figure 1) Patients’ subjective
expectations about their future HRQOL were associated
with their current HRQOL as measured by the EQ-5D
and also with their self-reported happiness. However,
current health state as assessed by the TTO method did
not correlate with subjective HRQOL expectations. Simi-
larly to differences of current HRQOL between genders,
men expected significantly better HRQOL for future ages
than women. Likewise, informal care utilisation reflecting
the dependence on others to perform everyday activities
negatively influenced not only the current HRQOL but
also future HRQOL expectations.
We compared AMD patients’ HRQOL expectations
for the future to findings from the age-matched partici-
pants of a similar study among the Hungarian general
population (Fig. 1) As future age increases the difference
becomes greater, and for age 90 AMD patients expect by
0.2 better EQ-5D utility than the general population.
However, in previously published studies patients with
rheumatoid arthritis and psoriasis expected a sharp de-
crease of their HRQOL with age and their expectations
were significantly more pessimistic than those of the
general public [32, 34]. Higher age might be a possible
explanation for AMD patients’ less pessimistic expecta-
tions, near future can be predicted easier. In our sample
age was in a positive correlation with HRQOL expecta-
tions and mean age of AMD patients (75 years) was
higher than either in rheumatoid arthritis, or in psoriasis
samples or in the general population. Patients’ confi-
dence in and experienced benefits with antiVEGF treat-
ment might also have positive impact. Prospective
studies are suggested to investigate further how patients’
experiences with antiVEGF treatment influence their
subjective HRQOL expectations for future ages.
Besides current and expected future HRQOL, patients
were asked about the age they expect to live. Subjective
life-expectancy of AMD patients was consistent with the
gender- and age-matched statistical life expectancy. This
result suggests that antiVEGF treated AMD patients do
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not expect the disease having a negative impact on their
length of life. Patients’ age and current happiness had
significant influence on estimation accuracy. Older and
happier patients expected more remaining life years than
statistically predicted. The association between subjective
life-expectancy and TTO was one of our points of interest,
nevertheless we found no significant correlation between
the two. We find important to note, however, that we used
patients’ self-estimated longevity for the TTO. Given the
similarities we found between subjective and statistical
life-expectancies applying the latter in TTO studies seems
to be a rational approach. Our results highlight that both
current health state valuations and subjective health ex-
pectations are influenced various non-medical factors
such as overall satisfaction with life (happiness) or de-
pendence on others and are worthy to consider in future
studies.
Comparing our results with other diseases, Rencz and
colleagues observed similarly exact life expectancy esti-
mation among psoriasis patients (N = 200, mean
age = 50 ± 12) [32]. Péntek and colleagues found no sig-
nificant difference either between the subjective life-
expectancy of rheumatoid arthritis patients initiating
biological treatment and actuarial life-expectancy
(N = 92, mean age: 52 ± 12 years) [34]. However, an
overestimation of subjective life-expectancy compared
to statistical life-expectancy was observed in a large
convenient sample of the general public in Hungary,
and the difference was especially large among men [13].
It is hard to draw firm conclusions based on indirect
comparisons. Nevertheless, these findings suggest that
in chronic illnesses, including AMD, patients’ subjective
expectations regarding remaining life years tend to lag
behind compared to those of the general population.
Findings of this empirical investigation should be
interpreted carefully given the limitations of the study.
The study involved a convenience sample of AMD pa-
tients from two university based referral centres. The
Hungarian statistical life expectancy data used for the
comparisons were merely gender- and age-matched, al-
though other socio-economic determinants, such as level
of education, marital status and monthly income, might
also have an impact on life expectancy. Due to the
cross-sectional study design and heterogeneity of our
sample in terms of biological treatment duration, we
were not able to analyse the effects of antiVEGF therapy
on subjective health expectations, a point that certainly
deserves further investigation.
Conclusions
Our findings suggest that AMD patients expect a signifi-
cant deterioration of health with age and predict to have
worse general health state in older ages than the general
population actually has. Nevertheless, they expect to live
as long as their age and gender matched counterparts in
the general public. Worse subjective health expectations
affect in particular the older patients in worse general
health state. The most influential factor both on current
HRQOL and future subjective health expectations was
informal care. AMD patients requiring others’ help for
self-care have worse HRQOL, expect shorter life and
lower HRQOL for future ages. Patients’ happiness in
general has deterministic role as well both in current
health status utility evaluation and subjective health ex-
pectations. These two patient-related factors (informal
care need and self-reported happiness) might be of
relevance also in chronic diseases other than AMD and
we encourage considering them in further health ex-
pectation studies. Results of our empirical investigation
highlight the importance of including issues of long-
term expectations in patient-clinician discussions in
AMD care, to have a better knowledge and understanding
of their perspective. Further longitudinal studies involving
larger samples should bring more evidence on the link
between subjective health expectations and actual health
outcomes and the generalizability of the results.
Additional file
Additional file 1: AMD questionnaire survey. The set of questions used
in the survey to assess health-related quality of life, subjective health
expectations and disease burden of patients with age-related macular
degeneration treated with antiVEGF drugs. (DOC 188 kb)
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